Login / Signup

Reply to: Frequent self-assessments in ALS clinical trials: Worthwhile or an unnecessary burden?

Seward B RutkovePushpa NarayanaswamiVisar BerishaJulie LissShira HahnKerisa SheltonKristin QiSarbesh PandeyaJeremy M Shefner
Published in: Annals of clinical and translational neurology (2020)
Keyphrases
  • clinical trial
  • amyotrophic lateral sclerosis
  • phase ii
  • risk factors
  • open label
  • study protocol
  • phase iii
  • randomized controlled trial